Mbx Biosciences (MBX) Market Update
Mbx Biosciences (ticker MBX) closed the trading day on Tuesday 20 October 2026 at a price of USD 53.50, an increase of 5.79 % over the previous close. The share price was reported at 11:23 PM Central Europe.
Trading Metrics
| Item | Value |
|---|---|
| Current price | USD 53.50 |
| Shares outstanding | 48.2 million |
| Market capitalization | USD 2.5 billion |
| 24‑hour volume | USD 27.4 million |
| 24‑hour change | +5.79 % |
| Monthly change (last month end) | –13.88 % |
| 200‑day simple moving average | USD 44.70 |
| 52‑week high | USD 72.64 (05 Aug 2026) |
| 52‑week low | USD 14.61 (23 Oct 2025) |
Recent Performance
- Last 24 hours: The stock traded +5.79 %, outperforming many peers in the sector.
- Monthly trend: Over the past month, MBX’s share price declined by 13.88 %.
- Liquidity: The 24‑hour volume of USD 27.4 million represents approximately 0.5 % of the company’s market cap.
Corporate News: Microbix Biosystems Inc.
Microbix Biosystems Inc., a Canadian life‑sciences company, announced that it will participate in the 38th International Papillomavirus Society (IPVS) conference in Athens, Greece. The company will present research on a novel synthetic vaginal matrix designed to support validation and quality control of HPV molecular assays.
Key points from the announcement:
- The matrix is renewable and can be used with dry controls to verify assay performance, including on self‑collected samples.
- Preliminary testing indicates performance comparable to traditional pooled vaginal matrix, with no assay interference.
- The matrix is positioned to facilitate the adoption of self‑collection workflows in laboratories and may have broader applications in women’s health and STI testing.
- Microbix continues to develop diagnostic support tools and maintains an extensive international distribution network.
Comparative Stock Performance (Last 24 hours)
| Company | Ticker | 24‑hour change | Current price | Market cap | P/E ratio (if available) |
|---|---|---|---|---|---|
| Polaris | PII | –0.33 % | USD 53.74 | USD 3 bn | – |
| Digitalbridge | DBRG | 0 % | USD 16.00 | USD 3 bn | 10.09 |
| Cal‑maine Foods | CALM | –2.53 % | USD 61.72 | USD 3 bn | 51.7 |
| Abm Industries | ABM | +0.51 % | USD 51.56 | USD 3 bn | 18.52 |
| Tarsus | TARS | +2.10 % | USD 71.03 | USD 3 bn | – |
Abm Industries – Additional Developments
Abm Industries’ Respiratory Care division has secured a growth‑capital commitment from Trinity Capital. The funding aims to:
- Accelerate commercial rollout of the BiWaze platform, which includes FDA‑cleared systems for airway clearance.
- Expand market presence in both hospital and home care settings.
- Support product development and clinical research for connected care technologies.
The investment is described as a significant milestone that will provide operational flexibility for the next growth phase and expand access to innovative respiratory therapies worldwide.
